These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

820 related items for PubMed ID: 17657815

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Impact of race on biochemical disease recurrence after prostate brachytherapy.
    Yamoah K, Stone N, Stock R.
    Cancer; 2011 Dec 15; 117(24):5589-600. PubMed ID: 21692058
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08.
    Voog JC, Paulus R, Shipley WU, Smith MR, McGowan DG, Jones CU, Bahary JP, Zeitzer KL, Souhami L, Leibenhaut MH, Rotman M, Husain SM, Gore E, Raben A, Chafe S, Sandler HM, Efstathiou JA.
    Eur Urol; 2016 Feb 15; 69(2):204-10. PubMed ID: 26362090
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Androgen deprivation increases the risk of fracture in prostate cancer patients: a population-based study in Chinese patients.
    Wu CT, Yang YH, Chen PC, Chen MF, Chen WC.
    Osteoporos Int; 2015 Sep 15; 26(9):2281-90. PubMed ID: 25990353
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial.
    Cormie P, Galvão DA, Spry N, Joseph D, Chee R, Taaffe DR, Chambers SK, Newton RU.
    BJU Int; 2015 Feb 15; 115(2):256-66. PubMed ID: 24467669
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer.
    O'Farrell S, Garmo H, Holmberg L, Adolfsson J, Stattin P, Van Hemelrijck M.
    J Clin Oncol; 2015 Apr 10; 33(11):1243-51. PubMed ID: 25732167
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy.
    Conteduca V, Di Lorenzo G, Tartarone A, Aieta M.
    Crit Rev Oncol Hematol; 2013 Apr 10; 86(1):42-51. PubMed ID: 23092636
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Long-term quality of life in disadvantaged men with prostate cancer on androgen-deprivation therapy.
    Sevilla C, Maliski SL, Kwan L, Connor SE, Litwin MS.
    Prostate Cancer Prostatic Dis; 2012 Sep 10; 15(3):237-43. PubMed ID: 22289781
    [Abstract] [Full Text] [Related]

  • 39. Competing risks for patients with localized prostate cancer.
    Seidenfeld J, Samson DJ, Albertsen PC.
    J Natl Cancer Inst; 2007 Oct 17; 99(20):1498-9. PubMed ID: 17925533
    [No Abstract] [Full Text] [Related]

  • 40. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer.
    Taylor LG, Canfield SE, Du XL.
    Cancer; 2009 Jun 01; 115(11):2388-99. PubMed ID: 19399748
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 41.